Evogene (EVGN) Misses Q4 EPS by 20c

Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.28 million versus the consensus estimate of $650 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Casey's General Stores (CASY) Tops Q1 EPS by 69c
• U.S. Bancorp (USB) Raises Quarterly Dividend 3.8% to $0.54; 3.5% Yield
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance